The SIGMA Group Chooses ExaGrid to Back Up Customer Data
25.6.2020 16:10:00 EEST | Business Wire | Press release
ExaGrid ® today announced that INFIDIS, a global IT integrator and solutions provider, led The SIGMA Group to choose ExaGrid’s tiered backup storage solution to enhance data protection and optimize its backups and data restoration capabilities, needed to offer its customers backup as a service.
The SIGMA Group is a digital services company based in France, specialized in software publishing, integration of tailor-made digital solutions, and outsourcing of information systems and cloud solutions. The SIGMA Group now uses ExaGrid to store customer backups, as well as its own backed up data, in addition to using ExaGrid to replicate data from its primary site to its disaster recovery (DR) site. Adding ExaGrid to The SIGMA Group’s backup environment has allowed the company to keep up with customer data growth and deliver on its SLAs.
“To meet Sigma's expectations, INFIDIS proposed the ExaGrid solution because of the many benefits it offers such as performance that is guaranteed over time, predictable costs, a scalable architecture which allows for progressive and granular investments as needed, very fast tape copy, and easily maintained long-term retention,” said Frédéric Floret, IT Business Engineer at INFIDIS.
“Using ExaGrid allows us to provide high-quality backup services to our customers,” said Mickaël Collet, cloud architect at The SIGMA Group. “We guarantee high SLAs especially on backup services and ExaGrid helps us to deliver on those. Our backup services include performance commitments on restorations and ExaGrid’s Landing Zone allows us to keep the freshest data in a non-deduplicated format to guarantee optimal restoration performance.”
The SIGMA Group is responsible for backing up 650TB of customer data, which is backed up in daily incrementals, as well as weekly and monthly fulls. The SIGMA Group’s IT staff have found that ExaGrid’s unique scale-out architecture has been helpful in keeping up with growing data. “We need to adjust capacity as closely as possible to customer needs and not have to oversize backup infrastructures based on growth forecasts,” said Alexandre Chaillou, infrastructure manager at The SIGMA Group. “We started with two ExaGrid systems, with one appliance at our primary data center and one at our remote data center. We expanded our two ExaGrid systems, which now are made up of 14 ExaGrid appliances. ExaGrid’s scale-out approach allows us to add capacity while making it possible to only add what is needed.”
ExaGrid writes backups directly to a disk-cache Landing Zone, avoiding inline processing and ensuring the highest possible backup performance, which results in the shortest backup window. Adaptive Deduplication performs deduplication and replication in parallel with backups while providing full system resources to the backups for the shortest backup window.
All of ExaGrid’s appliances contain not just disk but also processing power, memory, and bandwidth. When the system needs to expand, additional appliances are simply attached to the existing system. This type of configuration allows the system to maintain all the aspects of performance as the amount of data grows, allowing organizations to pay for what they need when they need it. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic.
Read the complete Success Story to learn more about The SIGMA Group’s experience using ExaGrid. ExaGrid’s published customer success stories and enterprise stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support.
About INFIDIS
INFIDIS is a 20-year-old global IT integrator and solutions provider that is in line with industry leaders. Its solution architects and engineers design, build, deliver and manage IT solutions and services for customers of all sizes and from a wide variety of industries.
INFIDIS help customers to adapt their infrastructures to the requirements of their businesses by offering them high-performance and secure solutions for the optimization of data centers in heterogeneous environments. INFIDIS offers an end-to-end support, independent of constructors and editors and based on a large ecosystem of skills, supplying all the necessary bricks to the building of the base of the new generation of infrastructures.
About ExaGrid
ExaGrid provides tiered backup storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005508/en/
Contact information
Media:
Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x248
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
